Lobradimil
Product Specifications
UNSPSC Description
Lobradimil (RMP 7), a synthetic bradykinin analog, is a potent and selective bradykinin B2 receptor agonist (Ki: 0.54 nM). Lobradimil increases the permeability of the BBB. Lobradimil can be used in the research of brain tumors[1].
Target Antigen
Bradykinin Receptor
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lobradimil.html
Purity
99.51
Solubility
H2O : ≥ 50 mg/mL
Smiles
O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N2[C@@H](C[C@H](C2)O)C(NCC(N[C@H](C(N[C@@H](CO)C(N3[C@@H](CCC3)C(N[C@H](CN[C@H](C(O)=O)CCCNC(N)=N)CC4=CC=C(C=C4)OC)=O)=O)=O)CC5=CC=CS5)=O)=O
Molecular Weight
1098.28
References & Citations
[1]Warren K, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2006 Sep;58(3):343-7. |[2]Elliott PJ, et al. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology. 1996 Jun;33(1-3):205-8. |[3]Doctrow SR, et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther. 1994 Oct;271(1):229-37. |[4]Mackic JB, et al. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res. 1999 Sep;16(9):1360-5.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-105155/Lobradimil-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-105155/Lobradimil-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
159768-75-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
